Log in

NASDAQ:CTICCTI BioPharma Stock Price, Forecast & News

$1.02
-0.01 (-0.97 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.00
Now: $1.02
$1.04
50-Day Range
$0.88
MA: $1.00
$1.13
52-Week Range
$0.62
Now: $1.02
$1.93
Volume105,413 shs
Average Volume179,833 shs
Market Capitalization$75.15 million
P/E RatioN/A
Dividend YieldN/A
Beta1.52
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; University of Vermont; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
Read More
CTI BioPharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTIC
Previous SymbolNASDAQ:CTICD
CUSIPN/A
Phone206-282-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.35 million
Book Value$0.30 per share

Profitability

Net Income$-40,020,000.00
Net Margins-177.54%

Miscellaneous

Employees46
Market Cap$75.15 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive CTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTIC and its competitors with MarketBeat's FREE daily newsletter.

CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions

How has CTI BioPharma's stock been impacted by COVID-19 (Coronavirus)?

CTI BioPharma's stock was trading at $0.8901 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CTIC shares have increased by 14.6% and is now trading at $1.02. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of CTI BioPharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CTI BioPharma.

When is CTI BioPharma's next earnings date?

CTI BioPharma is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for CTI BioPharma.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp (NASDAQ:CTIC) issued its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.07. CTI BioPharma had a negative net margin of 177.54% and a negative return on equity of 163.14%. View CTI BioPharma's earnings history.

When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?

CTI BioPharma's stock reverse split on the morning of Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CTIC?

1 brokers have issued 12 month target prices for CTI BioPharma's stock. Their forecasts range from $3.50 to $3.50. On average, they expect CTI BioPharma's share price to reach $3.50 in the next year. This suggests a possible upside of 243.1% from the stock's current price. View analysts' price targets for CTI BioPharma.

Has CTI BioPharma been receiving favorable news coverage?

News stories about CTIC stock have trended somewhat negative on Saturday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. CTI BioPharma earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the company's share price in the next several days. View the latest news aboutCTI BioPharma.

Who are some of CTI BioPharma's key competitors?

What other stocks do shareholders of CTI BioPharma own?

Who are CTI BioPharma's key executives?

CTI BioPharma's management team includes the following people:
  • Dr. Adam R. Craig, Pres, CEO, Interim Chief Medical Officer & Director (Age 53)
  • Dr. Jack W. Singer, Co-Founder & Consultant (Age 76)
  • Mr. David H. Kirske, Exec. VP, CFO & Sec. (Age 65)
  • Mr. Bruce J. Seeley, Exec. VP & COO (Age 55)
  • Mr. Ed Bell, Sr. Director of Investor Relations

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

Who are CTI BioPharma's major shareholders?

CTI BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (12.92%), NEA Management Company LLC (9.69%), Stonepine Capital Management LLC (8.73%), BlackRock Inc. (1.02%), Geode Capital Management LLC (0.56%) and Blair William & Co. IL (0.10%). View institutional ownership trends for CTI BioPharma.

Which major investors are selling CTI BioPharma stock?

CTIC stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP. View insider buying and selling activity for CTI BioPharma.

Which major investors are buying CTI BioPharma stock?

CTIC stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, NEA Management Company LLC, Stonepine Capital Management LLC, BlackRock Inc., Blair William & Co. IL, and Geode Capital Management LLC. View insider buying and selling activity for CTI BioPharma.

How do I buy shares of CTI BioPharma?

Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $1.02.

How big of a company is CTI BioPharma?

CTI BioPharma has a market capitalization of $75.15 million and generates $3.35 million in revenue each year. CTI BioPharma employs 46 workers across the globe.

What is CTI BioPharma's official website?

The official website for CTI BioPharma is www.ctibiopharma.com.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.